GET DAILY SIGNALSCentene (CNC) Delivers Q3 2026 Earnings Beat and Raises Full-Year Outlook
Key Takeaways
- Centene reported third-quarter 2026 adjusted diluted earnings per share (EPS) of $0.58, up 16% from $0.50 a year earlier and well ahead of Wall Street estimates.
- Total revenue reached $50.65 billion, rising 1.9% year over year and beating consensus forecasts by a wide margin.
- The company raised its full-year 2026 adjusted EPS guidance to more than $5.20 per share, up from a prior floor of $4.80.
- Medicare Advantage is now on track to reach breakeven in 2026, a full year ahead of management's original turnaround timeline.
- The consolidated health benefits ratio (HBR), which measures the share of premiums spent on medical claims, held steady at 92.7% and came in better than expected.
- Total membership declined to 25.7 million as Centene continued to manage through Medicaid eligibility changes and marketplace attrition.
Earnings Context and Why It Matters
Centene Corporation (NYSE: CNC), a leading U.S. managed care organization focused on government-sponsored health programs, delivered third-quarter 2026 results that underscore a meaningful inflection in its multiyear margin-recovery story. The report matters because Centene has spent recent quarters repairing profitability across its Medicaid, Medicare, and marketplace businesses while absorbing the effects of lower enrollment and the prior year's large goodwill impairment. A beat on earnings and revenue, combined with a raised full-year outlook and an earlier-than-expected Medicare Advantage breakeven, signals that management's cost and pricing discipline is translating into results. For investors, the update provides a clearer view into how Centene plans to balance shrinking membership with improving underwriting margins heading into 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Centene reported adjusted diluted EPS of $0.58 for the quarter ended September 30, 2026, up 16% from $0.50 a year ago and sharply above the consensus estimate of around $0.07. Total revenue came in at $50.65 billion, a 1.9% year-over-year increase that exceeded expectations. On a GAAP (Generally Accepted Accounting Principles) basis, the company posted a diluted loss per share of $0.14, reflecting severance and other optimization-related charges, while adjusted net earnings rose 18.4% to $290 million.
Premium and service revenue totaled $45.1 billion, up 0.5%, driven by Prescription Drug Plan (PDP) membership growth and Medicaid rate increases. The consolidated health benefits ratio held at 92.7%, better than expected and a 30-basis-point sequential improvement. Segment performance varied: Medicare revenue jumped 19.9% to $11.3 billion, Medicaid revenue rose 4% to $24.1 billion, and commercial revenue fell 21% to $8.7 billion amid marketplace attrition.
Market Reaction and Investor Sentiment
Investors responded favorably to the results, with Centene shares trading higher following the release and approaching a 52-week high. The positive reaction reflected the magnitude of the earnings beat, the upward revision to full-year guidance, and confirmation that the Medicare Advantage turnaround is progressing faster than planned. Sentiment was further supported by disciplined debt reduction, which lowered the company's total debt and interest expense. At the same time, attention remains focused on enrollment trends, as continued declines in Medicaid and marketplace membership are expected to persist into 2027, tempering some of the optimism around margin gains.
Forward Outlook and Key Factors to Monitor
Centene enters the fourth quarter with raised expectations. Management now projects full-year 2026 adjusted EPS above $5.20 and total revenue between $196.5 billion and $200.5 billion, with a full-year HBR target of roughly 90.4% to 91.1%. The company expects the Medicare Advantage segment to reach breakeven in 2026, a year ahead of schedule, and marketplace pretax margin is now seen at the top of its prior range.
Looking ahead, investors should watch several key factors. First, Medicaid membership is expected to decline 8% to 9% by year-end, and further attrition is anticipated in 2027 as states implement work requirements and eligibility terminations under the One Big Beautiful Bill Act (OB3). Roughly 40% of Medicaid revenue is scheduled to re-rate at the start of 2027, making state rate decisions a critical swing factor for margin stability.
Second, management has signaled that Medicare Advantage membership will likely be down year over year in 2027 as the company prioritizes margin expansion over growth, while PDP margins are expected to reset lower from their strong 2026 levels. Finally, cost trends in areas such as behavioral health, home health, and high-cost drugs, along with regulatory and program-integrity adjustments, will remain central to whether Centene can sustain its improved profitability into 2027. From what I see, these dynamics make the stock worth following closely into year-end.
Exploring AI Tools for Earnings Analysis
I often turn to Tickeron’s AI Screener when reviewing quarterly results like these. It helps me quickly filter healthcare names by fundamentals, technical patterns, and AI signals to put Centene’s performance in broader context without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CNC in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 12, 2026
CNC broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 43 similar instances where the stock broke above the upper band. In 31 of the 43 cases the stock fell afterwards. This puts the odds of success at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for CNC moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 21 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 61 cases where CNC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for CNC entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on CNC as a result. In 56 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for CNC just turned positive on October 06, 2026. Looking at past instances where CNC's MACD turned positive, the stock continued to rise in 35 of 48 cases over the following month. The odds of a continued upward trend are 73%.
CNC moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CNC crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNC advanced for three days, in 188 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. CNC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CNC's P/B Ratio (1.490) is slightly lower than the industry average of (3.470). P/E Ratio (-6.586) is within average values for comparable stocks, (127.042). Projected Growth (PEG Ratio) (0.754) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a multi-line healthcare enterprise
Industry ManagedHealthCare
Advertisement